Non-surgical therapies for early-stage non-small cell lung cancer a systematic review

Lung cancer is the leading cause of cancer-related deaths in the United States (US). The majority of lung cancers are diagnosed at advanced stages but with the advent of lung cancer screening, the number of individuals diagnosed with early-stage lung cancer has continued to rise. Within the Veterans...

Full description

Bibliographic Details
Main Author: Sultan, Shahnaz
Corporate Author: United States Department of Veterans Affairs
Format: eBook
Language:English
Published: Washington, DC U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service June 2023, 2023
Series:Evidence synthesis program
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 03119nam a2200229 u 4500
001 EB002180658
003 EBX01000000000000001318145
005 00000000000000.0
007 tu|||||||||||||||||||||
008 231009 r ||| eng
100 1 |a Sultan, Shahnaz 
245 0 0 |a Non-surgical therapies for early-stage non-small cell lung cancer  |h Elektronische Ressource  |b a systematic review  |c Shahnaz Sultan, Kristen Ullman, Elizabeth Ester, Anne Melzer, Maylen Anthony, Rosemary F. Kelly, Adrienne Landsteiner, Christopher Stampe, Jeffrey Thiboutot, Timothy J. Wilt 
260 |a Washington, DC  |b U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service  |c June 2023, 2023 
300 |a 1 PDF file (viii, 63 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a United States  |b Department of Veterans Affairs 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Evidence synthesis program 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK592710  |3 Volltext 
082 0 |a 610 
520 |a Lung cancer is the leading cause of cancer-related deaths in the United States (US). The majority of lung cancers are diagnosed at advanced stages but with the advent of lung cancer screening, the number of individuals diagnosed with early-stage lung cancer has continued to rise. Within the Veterans Health Administration (VA), approximately 8,000 Veterans are diagnosed with and treated for lung cancer every year. Surgery, including lobectomy, segmentectomy, wedge resection, and sleeve resection with or without the use of minimally invasive approaches, has been considered the standard of care for individuals with early-stage lung cancer who are deemed to be medically operable. Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) are frequently offered to individuals considered to be medically inoperable for various reasons (due to advanced age or with comorbidities that place them at high risk for severe perioperative complications). Promising results with SBRT/SABR in patients deemed to be medically inoperable have led to studies evaluating the efficacy and long-term outcomes of this therapy as an alternative to surgery in medically operable patients. These results raise questions about definitive treatment options for early-stage lung cancer. This review addresses important questions regarding the comparative effectiveness of surgery versus SBRT/SABR as well as the current body of evidence for ablative therapies such as radiofrequency ablation, cryoablation, microwave ablation, laser ablation, and brachytherapy in the management of medically operable stage I lung cancer. This topic was nominated by the National Radiation Oncology Program. Additionally, this review provides the background rationale for an ongoing VA Cooperative Study, a randomized trial of surgery versus SBRT (NCT02984761). Findings will be used to inform use of treatment modalities in patients with stage I lung cancer who are deemed medically operable